BEMFOLA follitropin alfa (rch) 300 IU/0.5 mL (22 microgram) solution for injection cartridge in a pre-filled pen Australia - angielski - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 300 iu/0.5 ml (22 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 300 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

BEMFOLA follitropin alfa (rch) 225 IU/0.375 mL (16.5 microgram) solution for injection cartridge in a pre-filled pen Australia - angielski - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 225 iu/0.375 ml (16.5 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 225 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

BEMFOLA follitropin alfa (rch) 150 IU/0.25 mL (11 microgram) solution for injection cartridge in a pre-filled pen Australia - angielski - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 150 iu/0.25 ml (11 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 150 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

BEMFOLA follitropin alfa (rch) 75 IU/0.125 mL (5.5 microgram) solution for injection cartridge in a pre-filled pen Australia - angielski - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 75 iu/0.125 ml (5.5 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 75 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

Suture knot pusher, reusable Australia - angielski - Department of Health (Therapeutic Goods Administration)

suture knot pusher, reusable

johnson & johnson medical pty ltd t/a depuy synthes - 45716 - suture knot pusher, reusable - a reusable, hand-held manual surgical instrument that enables the user performing an internal suturing procedure to advance suture knots.

REBIF 44 interferon beta-1a (rch) 132 microgram/1.5mL solution for injection multidose cartridge Australia - angielski - Department of Health (Therapeutic Goods Administration)

rebif 44 interferon beta-1a (rch) 132 microgram/1.5ml solution for injection multidose cartridge

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: methionine; acetic acid; mannitol; poloxamer; water for injections; benzyl alcohol; sodium hydroxide - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

PERGOVERIS follitropin alfa (rch) / lutropin alfa (rch) powder for injection vial with diluent vial Australia - angielski - Department of Health (Therapeutic Goods Administration)

pergoveris follitropin alfa (rch) / lutropin alfa (rch) powder for injection vial with diluent vial

merck healthcare pty ltd - follitropin alfa, quantity: 150 iu; lutropin alfa, quantity: 75 iu - injection, powder for - excipient ingredients: sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; methionine; polysorbate 20; phosphoric acid; sodium hydroxide - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

REBIF 44 interferon beta-1a (rch) 44 microgram/0.5mL injection pre-filled syringe Australia - angielski - Department of Health (Therapeutic Goods Administration)

rebif 44 interferon beta-1a (rch) 44 microgram/0.5ml injection pre-filled syringe

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

REBIF 44 interferon beta-1a (rch) 44 microgram/0.5mL injection pre-filled syringe autoinjector Australia - angielski - Department of Health (Therapeutic Goods Administration)

rebif 44 interferon beta-1a (rch) 44 microgram/0.5ml injection pre-filled syringe autoinjector

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Conquest Prestige 550 Fungicide Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

conquest prestige 550 fungicide

conquest crop protection pty ltd - propiconazole; liquid hydrocarbon - emulsifiable concentrate - propiconazole triazole active 550.0 g/l; liquid hydrocarbon solvent other 371.0 g/l - fungicide